Cardiotrophin‐1 therapy reduces disease severity in a murine model of glomerular disease
Physiological Reports · 2024
DOI: 10.14814/phy2.16129 ↗At a glance
Journal article in Physiological Reports, 2024. Written by Nuria Perretta-Tejedor and 7 co-authors. Institution: Developmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK. Major MEDLINE topics: Cytokines, Kidney Glomerulus, Mice, Inbred C57BL. 49 references. The full text is freely available (open access, CC BY 4.0). Funded by: Kidney Research UK, UKRI | Medical Research Council (MRC), Wellcome Trust (WT).
Abstract (original language)
Cardiotrophin‐1 (CT‐1), a member of the interleukin (IL)‐6 cytokine family, has renoprotective effects in mouse models of acute kidney disease and tubulointerstitial fibrosis, but its role in glomerular disease is unknown. To address this, we used the mouse model of nephrotoxic nephritis to test the hypothesis that CT‐1 also has a protective role in immune‐mediated glomerular disease. Using immunohistochemistry and analysis of single‐cell RNA‐sequencing data of isolated glomeruli, we demonstrate that CT‐1 is expressed in the glomerulus in male mice, predominantly in parietal epithelial cells and is downregulated in mice with nephrotoxic nephritis. Furthermore, analysis of data from patients revealed that human glomerular disease is also associated with reduced glomerular CT‐1 transcript levels. In male mice with nephrotoxic nephritis and established proteinuria, administration of CT‐1 resulted in reduced albuminuria, prevented podocyte loss, and sustained plasma creatinine, compared with mice administered saline. CT‐1 treatment also reduced fibrosis in the kidney cortex, peri‐glomerular macrophage accumulation and the kidney levels of the pro‐inflammatory mediator complement component 5a. In conclusion, CT‐1 intervention therapy delays the progression of glomerular disease in mice by preserving kidney function and inhibiting renal inflammation and fibrosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Developmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.
- UCL Centre for Kidney and Bladder Health, London, UK.
- Department of Physiology and Pharmacology, Translational Research on Renal and Cardiovascular Diseases (TRECARD), University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
- Specialised Foundation Programme in Research, NHS East of England, Cambridge, UK.
- Comparative Biomedical Sciences, The Royal Veterinary College, London, UK.
ORCID profiles: David A Long, Elisavet Vasilopoulou
Funding
- Kidney Research UK
- UKRI | Medical Research Council (MRC)
- Wellcome Trust (WT)
- Diabetes UK
- European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)
- Foulkes Foundation
- Medical Research Council
Cite
APA
Perretta-Tejedor, N., Price, K. L., Jafree, D. J., Pomeranz, G., Kolatsi-Joannou, M., Martínez-Salgado, C., Long, D. A., & Vasilopoulou, E. (2024). Cardiotrophin‐1 therapy reduces disease severity in a murine model of glomerular disease. Physiological Reports. https://doi.org/10.14814/phy2.16129
Vancouver
Perretta-Tejedor N, Price KL, Jafree DJ, Pomeranz G, Kolatsi-Joannou M, Martínez-Salgado C, et al. Cardiotrophin‐1 therapy reduces disease severity in a murine model of glomerular disease. Physiological Reports. 2024. doi:10.14814/phy2.16129
BibTeX
@article{PerrettaTejedor2024,
author = {Perretta-Tejedor, Nuria and Price, Karen L and Jafree, Daniyal J and Pomeranz, Gideon and Kolatsi-Joannou, Maria and Martínez-Salgado, Carlos and Long, David A and Vasilopoulou, Elisavet},
title = {Cardiotrophin‐1 therapy reduces disease severity in a murine model of glomerular disease},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.16129}
}
EUVIMED